Table 1. Patient characteristics.

Characteristics	Cap (N=36), n [%]	5-FU (N=32), n [%]	Total (N=68), n [%]	P value
Median age [95% CI]	64 [58–69]	58 [55–65]	60 [56–64]	0.33
Gender, female	21 [58]	17 [53]	38 [56]	0.81
Ethnicity/race				0.52
Caucasian	27 [75]	24 [75]	51 [75]
Hispanic	3 [8]	2 [6]	5 [7]
Black	2 [6]	0 [0]	2 [3]
Asian	1 [3]	1 [3]	2 [3]
Other	2 [6]	1 [3]	3 [4]
Missing	1 [3]	4 [13]	5 [7]
Stage (AJCC 7th edition)				0.38
Stage 1	8 [22]	5 [16]	13 [19]
Stage 2	15 [42]	19 [59]	34 [50]
Stage 3	13 [36]	8 [25]	21 [31]
Tumor size				0.47
≥5 cm	7 [19]	8 [25]	15 [22]
Missing	0 [0]	1 [3]	1 [1]
Node status, positive	9 [25]	8 [25]	17 [25]	1.00
ECOG status				0.57
0	11 [31]	11 [34]	22 [32]
1	21 [58]	13 [41]	34 [50]
2	4 [11]	2 [6]	6 [9]
3	0 [0]	1 [3]	1 [1]
Missing	0 [0]	5 [16]	5 [7]
Pathology, poorly differentiated	4 [11]	6 [19]	10 [15]	0.53
HIV status				0.30
Positive	1 [3]	3 [9]	4 [6]
Missing	16 [44]	16 [50]	32 [47]
Ever smoker, yes	17 [47]	18 [56]	35 [51]	0.48
Median date of diagnosis (95% CI)	1/18/2012 (6/8/2010–3/22/2013)	2/09/2008 (9/24/2003–3/24/2010)	05/28/2010 (7/02/2009–05/13/2011)	<0.001

Cap, capecitabine; 5-FU, 5 fluorouracil.